American Society of Hematology

Figure 1.

Timeline of major GVHD prophylaxis strategies for high-risk patients undergoing allogeneic hematopoietic cell transplantation.50,144-149 CSA, cyclosporin; Cy, cyclophosphamide; haplo-BMT, HLA-haploidentical bone marrow transplantation; MSD, matched sibling donor; PBSCT, peripheral blood stem cell transplantation; Siro, sirolimus; Tac, tacrolimus.

Timeline of major GVHD prophylaxis strategies for high-risk patients undergoing allogeneic hematopoietic cell transplantation.⁵⁰ ^,^144-149 CSA, cyclosporin; Cy, cyclophosphamide; haplo-BMT, HLA-haploidentical bone marrow transplantation; MSD, matched sibling donor; PBSCT, peripheral blood stem cell transplantation; Siro, sirolimus; Tac, tacrolimus.

This Feature Is Available To Subscribers Only